Evidence map›Paper›PMID 32604946›Full record

ArticleJournal of clinical medicine2020

Activated L-Arginine/Nitric Oxide Pathway in Pediatric Cystic Fibrosis and Its Association with Pancreatic Insufficiency, Liver Involvement and Nourishment: An Overview and New Results.

Folke Brinkmann, Beatrice Hanusch, Manfred Ballmann, Sebene Mayorandan, Alexander Bollenbach, Kristine Chobanyan-Jürgens, Kathrin Jansen, Anjona Schmidt-Choudhury, Nico Derichs, Dimitrios Tsikas and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Arginine at the host-pathogen interface.Infection and immunity · 2025
    Review
  2. Article
  3. Article
  4. Arginine Therapy for Lung Diseases.Frontiers in pharmacology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Folke BrinkmannUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
Beatrice HanuschUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
Manfred BallmannUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
Sebene MayorandanDepartment of Paediatrics, Hannover Medical School, 30623 Hannover, Germany.
Alexander BollenbachInstitute of Toxicology, Core Unit Proteomics, Hannover Medical School, 30623 Hannover, Germany.
Kristine Chobanyan-JürgensDepartment of Paediatrics, Hannover Medical School, 30623 Hannover, Germany.
Kathrin JansenUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
Anjona Schmidt-ChoudhuryUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
Nico DerichsDepartment of Paediatrics, Hannover Medical School, 30623 Hannover, Germany.
Dimitrios TsikasInstitute of Toxicology, Core Unit Proteomics, Hannover Medical School, 30623 Hannover, Germany.ORCID 0000-0001-6320-0956
Thomas LückeUniversity Children's Hospital, Ruhr University, 44791 Bochum, Germany.
University Hospitals of the Ruhr-University of Bochum · DEMedizinische Hochschule Hannover · DEHeidelberg University · DE

Funding

Merck Serono L-Arg-NO-CF-2009
6 · The paper itself

Abstract

Cystic fibrosis (CF; OMIM 219700) is a rare genetic disorder caused by a chloride channel defect, resulting in lung disease, pancreas insufficiency and liver impairment. Altered L-arginine (Arg)/nitric oxide (NO) metabolism has been observed in CF patients' lungs and in connection with malnutrition. The aim of the present study was to investigate markers of the Arg/NO pathway in the plasma and urine of CF patients and to identify possible risk factors, especially associated with malnutrition. We measured the major NO metabolites nitrite and nitrate, Arg, a semi-essential amino acid and NO precursor, the NO synthesis inhibitor asymmetric dimethylarginine (ADMA) and its major urinary metabolite dimethylamine (DMA) in plasma and urine samples of 70 pediatric CF patients and 78 age-matched healthy controls. Biomarkers were determined by gas chromatography-mass spectrometry and high-performance liquid chromatography. We observed higher plasma Arg (90.3 vs. 75.6 µM,

Indexed as

cystic fibrosisL-arginineliver diseasemalnutritionnitric oxidenitric oxide synthasesnutritional statuspancreatic disease

Identifiers

PMID32604946
PMCPMC7356307
OpenAlexW3038118317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.